Mariner’s Supernus Pharmaceuticals SUPN Stock Holding History

Mariner’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,557	Closed	-$218K	–	3796
2025 Q3	$218K	Buy	+4,557	New	+$184K	﹤0.01%	3102

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's SUPN Position: Q4 2025 in Review

Mariner sold out of Supernus Pharmaceuticals (SUPN) in Q4 2025, closing a stake of 4,557 shares — an estimated $218K sold.

Mariner first reported a position in SUPN in Q3 2025 and held it in 1 quarter. The position peaked at $218K in Q3 2025. 333 funds tracked by Wall St. Rank hold SUPN as of Q4 2025.

Mariner reported no remaining Supernus Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Mariner sold 4,557 Supernus Pharmaceuticals shares in Q4 2025, an estimated $218K.
Mariner first reported a position in Supernus Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Mariner's Supernus Pharmaceuticals position peaked at $218K in Q3 2025.
333 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2025.

Based on Mariner's 13F filing for Q4 2025, filed 13 Feb 2026.